0000950170-24-029907.txt : 20240312 0000950170-24-029907.hdr.sgml : 20240312 20240312160521 ACCESSION NUMBER: 0000950170-24-029907 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240308 FILED AS OF DATE: 20240312 DATE AS OF CHANGE: 20240312 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Emany Sravan Kumar CENTRAL INDEX KEY: 0001897662 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-34620 FILM NUMBER: 24742061 MAIL ADDRESS: STREET 1: 100 SUMMER ST STREET 2: SUITE 2300 CITY: BOSTON STATE: MA ZIP: 02109 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IRONWOOD PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001446847 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 043404176 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 SUMMER STREET, SUITE 2300 CITY: BOSTON STATE: MA ZIP: 02110 BUSINESS PHONE: 617-621-7722 MAIL ADDRESS: STREET 1: 100 SUMMER STREET, SUITE 2300 CITY: BOSTON STATE: MA ZIP: 02110 4 1 ownership.xml 4 X0508 4 2024-03-08 0001446847 IRONWOOD PHARMACEUTICALS INC IRWD 0001897662 Emany Sravan Kumar C/O IRONWOOD PHARMACEUTICALS, INC. 100 SUMMER STREET, SUITE 2300 BOSTON MA 02110 false true false false SVP, Chief Financial Officer false Class A Common Stock 2024-03-08 4 M false 37120 0 A 338853 D Performance-based Restricted Stock Unit 2024-03-08 4 M false 37120 0 D 2026-02-28 Class A Common Stock 37120 0 D Represents shares earned upon satisfaction of certain performance criteria associated with performance-based restricted stock units (PSUs) granted on March 8, 2023. The earned PSUs were certified on February 12, 2024, and March 7, 2024, and vested on March 8, 2024. Each PSU represents a contingent right to receive shares of the Issuer's Class A Common Stock upon vesting such award. The PSUs are earned upon the Issuer's Class A Common Stock achieving a specified price per share. Additional PSUs may vest upon the Issuer's Class A Common Stock achieving specified prices per share beyond the previously achieved vesting targets. /s/ Brian Tessler, Attorney-in-Fact 2024-03-12